{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T12:19:13Z","timestamp":1767961153325,"version":"3.49.0"},"reference-count":111,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2001,12,1]],"date-time":"2001-12-01T00:00:00Z","timestamp":1007164800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Resistance Updates"],"published-print":{"date-parts":[[2001,12]]},"DOI":"10.1054\/drup.2002.0230","type":"journal-article","created":{"date-parts":[[2002,9,19]],"date-time":"2002-09-19T10:55:24Z","timestamp":1032432924000},"page":"392-401","source":"Crossref","is-referenced-by-count":111,"title":["Anticancer therapy with novel tubulin-interacting drugs"],"prefix":"10.1054","volume":"4","author":[{"given":"Maria","family":"Kavallaris","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole M.","family":"Verrills","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bridget T.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1054\/drup.2002.0230_RF1","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1146\/annurev.bi.62.070193.002125","article-title":"Biochemistry of multidrug resistance mediated by the multidrug transporter","volume":"62","author":"Gottesman","year":"1993","journal-title":"Annu Rev Biochem"},{"key":"10.1054\/drup.2002.0230_RF2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/00001813-199701000-00002","article-title":"The role of Multidrug Resistance-associated Protein (MRP) gene expression in drug resistance","volume":"8","author":"Kavallaris","year":"1997","journal-title":"Anti-Cancer Drugs"},{"key":"10.1054\/drup.2002.0230_RF3","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1093\/jnci\/92.16.1295","article-title":"A family of drug transporters: the multidrug resistance-associated proteins","volume":"92","author":"Borst","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1054\/drup.2002.0230_RF4","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1093\/jnci\/91.5.429","article-title":"Atypical multidrug resistance: Breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines","volume":"91","author":"Ross","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"10.1054\/drup.2002.0230_RF5","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1172\/JCI119642","article-title":"Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific \u03b2-tubulin isotypes","volume":"100","author":"Kavallaris","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1054\/drup.2002.0230_RF6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1054\/drup.2000.0172","article-title":"Factors determining cellular mechanisms of resistance to antimitotic drugs","volume":"4","author":"Cabral","year":"2001","journal-title":"Drug Resist Updates"},{"key":"10.1054\/drup.2002.0230_RF7","first-page":"1","article-title":"The role of \u03b2-tubulin isotypes in resistance to antimitotic drugs","volume":"1471","author":"Burkhart","year":"2001","journal-title":"Biochim Biophys Acta"},{"key":"10.1054\/drup.2002.0230_RF8","first-page":"5803","article-title":"Multiple microtubule alterations are associated with vinca alkaloid resistance in human leukaemia cells","volume":"61","author":"Kavallaris","year":"2001","journal-title":"Cancer Res"},{"key":"10.1054\/drup.2002.0230_RF9","doi-asserted-by":"crossref","first-page":"17118","DOI":"10.1074\/jbc.272.27.17118","article-title":"Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization","volume":"272","author":"Giannakakou","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1054\/drup.2002.0230_RF10","doi-asserted-by":"crossref","first-page":"23875","DOI":"10.1074\/jbc.274.34.23875","article-title":"A \u03b2-tubulin leucine cluster involved in microtubule assembly and paclitaxel resistance","volume":"274","author":"Gonzalez-Garay","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1054\/drup.2002.0230_RF11","first-page":"3","article-title":"Mutations in \u03b2-tubulin map to domains involved in regulation of microtubule stability in epothilone-resistant cell lines","volume":"1","author":"He","year":"2001","journal-title":"Mol Cancer Therapeut"},{"key":"10.1054\/drup.2002.0230_RF12","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1073\/pnas.77.3.1561","article-title":"Taxol stabilizes microtubules in mouse fibroblast cells","volume":"77","author":"Schiff","year":"1980","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1054\/drup.2002.0230_RF13","doi-asserted-by":"crossref","first-page":"9552","DOI":"10.1073\/pnas.90.20.9552","article-title":"Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations","volume":"90","author":"Jordan","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1054\/drup.2002.0230_RF14","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1021\/bi00007a014","article-title":"Substoichiometric binding of taxol suppresses microtubule dynamics","volume":"34","author":"Derry","year":"1995","journal-title":"Biochemistry"},{"key":"10.1054\/drup.2002.0230_RF15","first-page":"5045","article-title":"Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules","volume":"60","author":"Ngan","year":"2000","journal-title":"Cancer Res"},{"key":"10.1054\/drup.2002.0230_RF16","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.2174\/1381612013397483","article-title":"Modifications in the \u201cupper\u201d velbenamine part of the vinca alkaloids have major implications for tubulin interacting activities","volume":"7","author":"Fahy","year":"2001","journal-title":"Curr Pharm Des"},{"key":"10.1054\/drup.2002.0230_RF17","series-title":"Antimicrotubule Agents","first-page":"467","author":"Rowinsky","year":"1997"},{"key":"10.1054\/drup.2002.0230_RF18","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S1040-8428(01)00183-4","article-title":"Vinflunine, the latest vinca alkaloid in clinical development. A review of its preclinical anticancer properties","volume":"40","author":"Kruczynski","year":"2001","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1054\/drup.2002.0230_RF19","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.2174\/1381612013397456","article-title":"Vinflunine, a second generation novel vinca alkaloid with a distinctive pharmacological profile, now in clinical development and prospects for future mitotic blockers","volume":"7","author":"Hill","year":"2001","journal-title":"Curr Pharm Des"},{"key":"10.1054\/drup.2002.0230_RF20","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1124\/mol.60.1.225","article-title":"Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic vinca alkaloids vinorelbine and its newer derivative vinflunine","volume":"60","author":"Ngan","year":"2001","journal-title":"Mol Pharmacol"},{"key":"10.1054\/drup.2002.0230_RF21","article-title":"How do the newer vinca alkaloids vinflunine and vinorelbine block mitosis","volume":"43","author":"Okouneva","year":"2002","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.1054\/drup.2002.0230_RF22","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1054\/bjoc.2000.1587","article-title":"Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model","volume":"84","author":"Holwell","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1054\/drup.2002.0230_RF23","article-title":"Significant antiangiogenic activity and marked inhibition of growth of an orthotopic colon cancer model and colon cancer liver metastases by vinflunine, the most recent vinca alkaloid in clinical development","volume":"43","author":"Kruczynski","year":"2002","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.1054\/drup.2002.0230_RF24","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s002800100275","article-title":"Markedly diminished drug-resistance inducing properties of vinflunine (20\u2032,20\u2032- difluoro-3\u2032,4\u2032- dihydrovinorelbine) relative to vinorelbine, identified in murine and human tumour cells in vivo and in vitro, with clinical implications","volume":"48","author":"Eti\u00e9vant","year":"2001","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1054\/drup.2002.0230_RF25","doi-asserted-by":"crossref","first-page":"9313","DOI":"10.1073\/pnas.95.16.9313","article-title":"Antiproliferative mechanisms of action of cryptophycin-52:Kinetic stabilization of microtubule dynamics by high-affinity binding to microtubule ends","volume":"95","author":"Panda","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1054\/drup.2002.0230_RF26","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s002800000210","article-title":"Cryptophycin-induced hyperphosphorylation of Bcl-2, cell cycle arrest and growth inhibition in human H460 NSCLC cells","volume":"47","author":"Lu","year":"2001","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1054\/drup.2002.0230_RF27","first-page":"471","article-title":"Cryptophycin 52 and cryptophycin 55 in sequential and simultaneous combination treatment regimens in human tumour xenografts","volume":"14","author":"Teicher","year":"2000","journal-title":"In Vivo"},{"key":"10.1054\/drup.2002.0230_RF28","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s002800000135","article-title":"Antitumour activity of cryptophycins: effect of infusion time and combination studies","volume":"46","author":"Menon","year":"2000","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1054\/drup.2002.0230_RF29","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.2174\/1381612013397474","article-title":"Cryptophycins: A novel class of potent antitumor depsipeptides","volume":"7","author":"Shih","year":"2001","journal-title":"Curr Pharm Des"},{"key":"10.1054\/drup.2002.0230_RF30","first-page":"965","article-title":"Interaction of dolastatin 10 with tubulin: induction of aggregation and binding and dissociation reactions","volume":"47","author":"Bai","year":"1995","journal-title":"Mol Pharmacol"},{"key":"10.1054\/drup.2002.0230_RF31","first-page":"525","article-title":"Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors","volume":"5","author":"Pitot","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1054\/drup.2002.0230_RF32","first-page":"4205","article-title":"Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma","volume":"6","author":"Vaishampayan","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1054\/drup.2002.0230_RF33","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1023\/A:1010626230081","article-title":"Dolastatin-10 in metastatic melanoma: a phase II and pharmokinetic trial of the California Cancer Consortium","volume":"19","author":"Margolin","year":"2002","journal-title":"Invest New Drugs"},{"key":"10.1054\/drup.2002.0230_RF34","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/j.1349-7006.2000.tb01022.x","article-title":"TZT-1027, an antimicrotubule agent, attacks tumor vasculature and induces tumor cell death","volume":"91","author":"Otani","year":"2000","journal-title":"Jpn J Cancer Res"},{"key":"10.1054\/drup.2002.0230_RF35","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/j.1349-7006.2000.tb01007.x","article-title":"Characterization of the interaction of TZT-1027, a potent antitumor agent, with tubulin","volume":"91","author":"Natsume","year":"2000","journal-title":"Jpn J Cancer Res"},{"key":"10.1054\/drup.2002.0230_RF36","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0378-4274(01)00327-7","article-title":"An antimicrotubule agent, TZT-1027, does not induce neuropathologic alterations which are detected after administration of vincristine or paclitaxel in animal models","volume":"121","author":"Ogawa","year":"2001","journal-title":"Toxicol Lett"},{"key":"10.1054\/drup.2002.0230_RF37","first-page":"392","article-title":"D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity","volume":"61","author":"Bacher","year":"2001","journal-title":"Cancer Res"},{"key":"10.1054\/drup.2002.0230_RF38","first-page":"5480","article-title":"A-204197, a new tubulin-binding agent with antimitotic activity in tumor cell lines resistant to known microtubule inhibitors","volume":"61","author":"Tahir","year":"2001","journal-title":"Cancer Res"},{"key":"10.1054\/drup.2002.0230_RF39","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1021\/jm010231w","article-title":"New antimitotic agents with activity in multi-drug resistant cell lines and in vivo efficacy in murine tumor models","volume":"44","author":"Szczepankiewicz","year":"2001","journal-title":"J Med Chem"},{"key":"10.1054\/drup.2002.0230_RF40","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1021\/ja00738a045","article-title":"Plant antitumor agents VI. The isolation and structure of taxol, a novel antileukemic and antitumour agent fromtaxus brevifolia","volume":"93","author":"Wani","year":"1971","journal-title":"J Am Chem Soc"},{"key":"10.1054\/drup.2002.0230_RF41","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/0165-6147(92)90048-B","article-title":"Mechanism of action of taxol","volume":"13","author":"Horwitz","year":"1992","journal-title":"Trends Pharmacol Sci"},{"key":"10.1054\/drup.2002.0230_RF42","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/34465","article-title":"Structure of the \u03b1\u03b2 tubulin dimer by electron crystallography","volume":"391","author":"Nogales","year":"1998","journal-title":"Nature"},{"key":"10.1054\/drup.2002.0230_RF43","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0092-8674(00)80961-7","article-title":"High resolution model of the microtubule","volume":"96","author":"Nogales","year":"1999","journal-title":"Cell"},{"key":"10.1054\/drup.2002.0230_RF44","doi-asserted-by":"crossref","first-page":"R65","DOI":"10.1016\/S1074-5521(99)89002-4","article-title":"How Taxol stabilises microtubule structure","volume":"6","author":"Amos","year":"1999","journal-title":"Chem Biol"},{"key":"10.1054\/drup.2002.0230_RF45","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1146\/annurev.cellbio.16.1.89","article-title":"Structural basis for the interaction of tubulin with proteins and drugs that affect microtubule stability","volume":"16","author":"Downing","year":"2000","journal-title":"Annu Rev Cell Dev Biol"},{"key":"10.1054\/drup.2002.0230_RF46","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1177\/10600280940280S503","article-title":"Pharmacology and toxicology of cremophor EL diluent","volume":"28","author":"Dorr","year":"1994","journal-title":"Ann Pharmacother"},{"key":"10.1054\/drup.2002.0230_RF47","first-page":"22","article-title":"Docetaxel (Taxotere): an effective agent in the management of second-line breast cancer","volume":"22","author":"van Oosterom","year":"1995","journal-title":"Semin Oncol"},{"key":"10.1054\/drup.2002.0230_RF48","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1146\/annurev.med.48.1.353","article-title":"The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents","volume":"48","author":"Rowinsky","year":"1997","journal-title":"Annu Rev Med"},{"key":"10.1054\/drup.2002.0230_RF49","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.2174\/1381612013397465","article-title":"Preclinical evaluation of new taxoids","volume":"7","author":"Bissery","year":"2001","journal-title":"Curr Pharm Des"},{"key":"10.1054\/drup.2002.0230_RF50","first-page":"106a","article-title":"Phase I and Pharmacokinetic Study of RPR116258A, a Novel Taxane Derivative, Administered Intravenously over 1 Hour Every 3 Weeks","volume":"20","author":"Goetz","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1054\/drup.2002.0230_RF51","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1200\/JCO.2000.18.17.3164","article-title":"Phase I and pharmacokinetic study of a new taxoid, RPR 109881A, given as a 1-hour intravenous infusion in patients with advanced solid tumors","volume":"18","author":"Kurata","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1054\/drup.2002.0230_RF52","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s002800000241","article-title":"Preclinical antitumor activity of two novel taxanes","author":"Rose","year":"2001","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1054\/drup.2002.0230_RF53","first-page":"106a","article-title":"A phase I and pharmacokinetic (PK) study of the novel taxane BMS 184476 administered As a 1-hour intravenous (IV) infusion weekly","volume":"20","author":"Beeram","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1054\/drup.2002.0230_RF54","first-page":"86b","article-title":"Phase I Study of BMS-188797, a New Taxane Analog, Given Weekly in Patients with Advanced Malignancies","volume":"20","author":"Goldstein","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1054\/drup.2002.0230_RF55","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s002800000137","article-title":"Preclinical oral antitumor activity of BMS-185660, a paclitaxel derivative","volume":"46","author":"Rose","year":"2000","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1054\/drup.2002.0230_RF56","first-page":"842","article-title":"IDN5109, a taxane with oral bioavailability and potent antitumor activity","volume":"60","author":"Nicoletti","year":"2000","journal-title":"Cancer Res"},{"key":"10.1054\/drup.2002.0230_RF57","doi-asserted-by":"crossref","first-page":"560","DOI":"10.7164\/antibiotics.49.560","article-title":"Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria)","volume":"49","author":"Gerth","year":"1996","journal-title":"J Antibiot"},{"key":"10.1054\/drup.2002.0230_RF58","first-page":"2325","article-title":"Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action","volume":"55","author":"Bollag","year":"1995","journal-title":"Cancer Res"},{"key":"10.1054\/drup.2002.0230_RF59","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1074\/jbc.272.4.2534","article-title":"Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R))","volume":"272","author":"Kowalski","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1054\/drup.2002.0230_RF60","first-page":"3344","article-title":"stabilizes microtubuli of macrophages like taxol without showing taxol-like endotoxin activity","volume":"57","author":"Muhlradt","year":"1997","journal-title":"Cancer Res"},{"key":"10.1054\/drup.2002.0230_RF61","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/387268a0","article-title":"Synthesis of epothilones A and B in solid and solution phase","volume":"387","author":"Nicolaou","year":"1997","journal-title":"Nature"},{"key":"10.1054\/drup.2002.0230_RF62","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S1074-5521(98)90070-9","article-title":"Synthesis and biological properties of C12,13-cyclopropyl-epothilone A and related epothilones","volume":"5","author":"Nicolaou","year":"1998","journal-title":"Chem Biol"},{"key":"10.1054\/drup.2002.0230_RF63","doi-asserted-by":"crossref","first-page":"7456","DOI":"10.1021\/jo0007480","article-title":"Total syntheses of epothilones B and D","volume":"65","author":"Mulzer","year":"2000","journal-title":"J Org Chem"},{"key":"10.1054\/drup.2002.0230_RF64","first-page":"M79","article-title":"Epothilones and related structures\u2013a new class of microtubule inhibitors with potent in vivo antitumor activity","volume":"1470","author":"Altmann","year":"2000","journal-title":"Biochim Biophys Acta"},{"key":"10.1054\/drup.2002.0230_RF65","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1021\/ol005932m","article-title":"On the total synthesis and preliminary biological evaluations of 15(R) and 15(S) aza-dEpoB: a Mitsunobu inversion at C15 in pre-epothilone fragments","volume":"2","author":"Stachel","year":"2000","journal-title":"Org Lett"},{"key":"10.1054\/drup.2002.0230_RF66","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1073\/pnas.96.8.4256","article-title":"A common pharmacophore for cytotoxic natural products that stabilize microtubules","volume":"96","author":"Ojima","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1054\/drup.2002.0230_RF67","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1021\/bi992518p","article-title":"A common pharmacophore for Taxol and the epothilones based on the biological activity of a taxane molecule lacking a C-13 side chain","volume":"39","author":"He","year":"2000","journal-title":"Biochemistry"},{"key":"10.1054\/drup.2002.0230_RF68","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1073\/pnas.040546297","article-title":"A common pharmacophore for epothilone and taxanes: Molecular basis for drug resistance conferred by tubulin mutations in human cancer cells","volume":"97","author":"Giannakakou","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1054\/drup.2002.0230_RF69","doi-asserted-by":"crossref","first-page":"9642","DOI":"10.1073\/pnas.95.16.9642","article-title":"Desoxyepothilone B: an efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothilone B","volume":"95","author":"Chou","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1054\/drup.2002.0230_RF70","doi-asserted-by":"crossref","first-page":"15798","DOI":"10.1073\/pnas.95.26.15798","article-title":"Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel","volume":"95","author":"Chou","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1054\/drup.2002.0230_RF71","first-page":"1429","article-title":"BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy","volume":"7","author":"Lee","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1054\/drup.2002.0230_RF72","first-page":"1168","article-title":"Clinical trials referral resource","volume":"15","author":"Colevas","year":"2001","journal-title":"Current clinical trials of epothilone B analog (BMS-247550). Oncology"},{"key":"10.1054\/drup.2002.0230_RF73","doi-asserted-by":"crossref","first-page":"8113","DOI":"10.1073\/pnas.131153098","article-title":"The synthesis, discovery, and development of a highly promising class of microtubule stabilization agents: curative effects of desoxyepothilones B and F against human tumor xenografts in nude mice","volume":"98","author":"Chou","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1054\/drup.2002.0230_RF74","doi-asserted-by":"crossref","first-page":"5490","DOI":"10.1021\/bi983023n","article-title":"The coral-derived natural products eleutherobin and sarcodictyins A and B: effects on the assembly of purified tubulin with and without microtubule- associated proteins and binding at the polymer taxoid site","volume":"38","author":"Hamel","year":"1999","journal-title":"Biochemistry"},{"key":"10.1054\/drup.2002.0230_RF75","first-page":"1111","article-title":"Eleutherobin, a novel cytotoxic agent that induces tubulin polymerization, is similar to paclitaxel (Taxol)","volume":"58","author":"Long","year":"1998","journal-title":"Cancer Res"},{"key":"10.1054\/drup.2002.0230_RF76","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1248\/cpb.47.1199","article-title":"Total synthesis and chemical biology of the sarcodictyins","volume":"47","author":"Nicolaou","year":"1999","journal-title":"Chem Pharm Bull"},{"key":"10.1054\/drup.2002.0230_RF77","first-page":"653","article-title":"Laulimalide and isolaulimalide, new paclitaxel-like microtubule-stabilizing agents","volume":"59","author":"Mooberry","year":"1999","journal-title":"Cancer Res"},{"key":"10.1054\/drup.2002.0230_RF78","doi-asserted-by":"crossref","unstructured":"Longley, R. E. Caddigan, D. Harmody, D. Discodermolide\u2013a new, marine-derived immunosuppressive compound, 1991, 52, 650, 656","DOI":"10.1097\/00007890-199110000-00015"},{"key":"10.1054\/drup.2002.0230_RF79","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1749-6632.1993.tb17145.x","article-title":"Immunosuppression by discodermolide","volume":"696","author":"Longley","year":"1993","journal-title":"Ann N Y Acad Sci"},{"key":"10.1054\/drup.2002.0230_RF80","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1021\/bi9515127","article-title":"Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than taxol","volume":"35","author":"ter Haar","year":"1996","journal-title":"Biochemistry"},{"key":"10.1054\/drup.2002.0230_RF81","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S1074-5521(96)90108-8","article-title":"(+)-Discodermolide binds to microtubules in stoichiometric ratio to tubulin dimers, blocks taxol binding and results in mitotic arrest","volume":"3","author":"Hung","year":"1996","journal-title":"Chem Biol"},{"key":"10.1054\/drup.2002.0230_RF82","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1124\/mol.52.4.613","article-title":"The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells","volume":"52","author":"Kowalski","year":"1997","journal-title":"Mol Pharmacol"},{"key":"10.1054\/drup.2002.0230_RF83","first-page":"1978","article-title":"Taxol and discodermolide represent a synergistic drug combination in human carcinoma cell lines","volume":"6","author":"Martello","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1054\/drup.2002.0230_RF84","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1021\/ol9910870","article-title":"Gram-scale synthesis of (+)-discodermolide","volume":"1","author":"Smith","year":"1999","journal-title":"Org Lett"},{"key":"10.1054\/drup.2002.0230_RF85","doi-asserted-by":"crossref","first-page":"9535","DOI":"10.1021\/ja011211m","article-title":"A practical synthesis of (+)-discodermolide and analogues: fragment union by complex aldol reactions","volume":"123","author":"Paterson","year":"2001","journal-title":"J Am Chem Soc"},{"key":"10.1054\/drup.2002.0230_RF86","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1021\/np000423e","article-title":"Acetylated analogues of the microtubule-stabilizing agent discodermolide: preparation and biological activity","volume":"64","author":"Gunasekera","year":"2001","journal-title":"J Nat Prod"},{"key":"10.1054\/drup.2002.0230_RF87","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1023\/A:1008348010437","article-title":"Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial","volume":"11","author":"Sarris","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1054\/drup.2002.0230_RF88","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1200\/JCO.1999.17.2.697","article-title":"Phase I study of liposomal vincristine","volume":"17","author":"Gelmon","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1054\/drup.2002.0230_RF89","first-page":"3258","article-title":"Paclitaxel liposome aerosol treatment induces inhibition of pulmonary metastases in murine renal carcinoma model","volume":"7","author":"Koshkina","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1054\/drup.2002.0230_RF90","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1471-4892(01)00064-9","article-title":"Past and future of the mitotic spindle as an oncology target","volume":"1","author":"Wood","year":"2001","journal-title":"Curr Opin Pharmacol"},{"key":"10.1054\/drup.2002.0230_RF91","first-page":"3229","article-title":"Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel","volume":"7","author":"Bradley","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1054\/drup.2002.0230_RF92","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0168-3659(01)00321-2","article-title":"Tumor targeting by conjugation of DHA to paclitaxel","volume":"74","author":"Bradley","year":"2001","journal-title":"J Control Rel"},{"key":"10.1054\/drup.2002.0230_RF93","first-page":"198","article-title":"Technology evaluation: C242-DM1, ImmunoGen Inc","volume":"3","author":"Smith","year":"2001","journal-title":"Curr Opin Mol Ther"},{"key":"10.1054\/drup.2002.0230_RF94","first-page":"111a","article-title":"Phase I and Pharmacological Study of CT-2103, a Poly (L-glutamic Acid)-Paclitaxel Conjugate","volume":"20","author":"Todd","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1054\/drup.2002.0230_RF95","first-page":"109a","article-title":"A Novel Oral Taxane (BMS-275183): a Phase I Trial with Evaluation of Pharmacokinetics, Pharmacodynamics and Bioavailability","volume":"20","author":"Trump","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1054\/drup.2002.0230_RF96","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1074-5521(00)00101-0","article-title":"Dissecting cellular processes using small molecules: identification of colchicine-like, taxol-like and other small molecules that perturb mitosis","volume":"7","author":"Haggarty","year":"2000","journal-title":"Chem Biol"},{"key":"10.1054\/drup.2002.0230_RF97","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1023\/A:1008398725442","article-title":"A phase I study of rhizoxin (NSC 332598) by 72-hour continuous intravenous infusion in patients with advanced solid tumors","volume":"11","author":"Tolcher","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1054\/drup.2002.0230_RF98","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1021\/jm9604080","article-title":"Syntheses and structure-activity relationships of the second-generation antitumor taxoids: exceptional activity against drug-resistant cancer cells","volume":"39","author":"Ojima","year":"1996","journal-title":"J Med Chem"},{"key":"10.1054\/drup.2002.0230_RF99","first-page":"2016","article-title":"Preclinical pharmacology of BMS-275183, an orally active taxane","volume":"7","author":"Rose","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1054\/drup.2002.0230_RF100","first-page":"2404","article-title":"Complete regression of well-established tumors using a novel water-soluble poly(L-glutamic acid)-paclitaxel conjugate","volume":"58","author":"Li","year":"1998","journal-title":"Cancer Res"},{"key":"10.1054\/drup.2002.0230_RF101","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s002800000168","article-title":"Biodistribution of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in mice with ovarian OCa-1 tumor","volume":"46","author":"Li","year":"2000","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1054\/drup.2002.0230_RF102","first-page":"125","article-title":"Comparison of action of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in human breast cancer cell","volume":"16","author":"Oldham","year":"2000","journal-title":"Int J Oncol"},{"key":"10.1054\/drup.2002.0230_RF103","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s002800050630","article-title":"An investigation of the antitumour activity and biodistribution of polymeric micellar paclitaxel","volume":"40","author":"Zhang","year":"1997","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1054\/drup.2002.0230_RF104","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1097\/00001813-199708000-00008","article-title":"Anti-tumor efficacy and biodistribution of intravenous polymeric micellar paclitaxel","volume":"8","author":"Zhang","year":"1997","journal-title":"Anticancer Drugs"},{"key":"10.1054\/drup.2002.0230_RF105","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1021\/js960333n","article-title":"Human plasma distribution of free paclitaxel and paclitaxel associated with diblock copolymers","volume":"86","author":"Ramaswamy","year":"1997","journal-title":"J Pharm Sci"},{"key":"10.1054\/drup.2002.0230_RF106","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/1097-0045(20000701)44:2<156::AID-PROS8>3.0.CO;2-8","article-title":"Polymeric micellar paclitaxel phosphorylates Bcl-2 and induces apoptotic regression of androgen-independent LNCaP prostate tumors","volume":"44","author":"Leung","year":"2000","journal-title":"Prostate"},{"key":"10.1054\/drup.2002.0230_RF107","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/00001813-200104000-00003","article-title":"Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel","volume":"12","author":"Meerum Terwogt","year":"2001","journal-title":"Anticancer Drugs"},{"key":"10.1054\/drup.2002.0230_RF108","doi-asserted-by":"crossref","first-page":"204","DOI":"10.7164\/antibiotics.53.204","article-title":"A new antimitotic substance, FR182877","volume":"53","author":"Sato","year":"2000","journal-title":"J Antibiot"},{"key":"10.1054\/drup.2002.0230_RF109","doi-asserted-by":"crossref","first-page":"123","DOI":"10.7164\/antibiotics.53.123","article-title":"A new antimitotic substance, FR182877","volume":"53","author":"Sato","year":"2000","journal-title":"J Antibiot"},{"key":"10.1054\/drup.2002.0230_RF110","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1054\/drup.2000.0165","article-title":"The relevance of drug sequence in combination chemotherapy","volume":"3","author":"Shah","year":"2000","journal-title":"Drug Resist Updates"},{"key":"10.1054\/drup.2002.0230_RF111","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1054\/drup.2000.0164","article-title":"Does P-glycoprotein play a role in anticancer drug pharmacokinetics","volume":"3","author":"Sparreboom","year":"2000","journal-title":"Drug Resist Updates"}],"container-title":["Drug Resistance Updates"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S136876460290230X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S136876460290230X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,2,6]],"date-time":"2020-02-06T17:48:20Z","timestamp":1581011300000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S136876460290230X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,12]]},"references-count":111,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2001,12]]}},"alternative-id":["S136876460290230X"],"URL":"https:\/\/doi.org\/10.1054\/drup.2002.0230","relation":{},"ISSN":["1368-7646"],"issn-type":[{"value":"1368-7646","type":"print"}],"subject":[],"published":{"date-parts":[[2001,12]]}}}